nodes	percent_of_prediction	percent_of_DWPC	metapath
Iloperidone—CYP1A2—Imiquimod—skin cancer	0.115	0.164	CbGbCtD
Iloperidone—CYP2E1—Dacarbazine—skin cancer	0.0835	0.119	CbGbCtD
Iloperidone—CYP1A2—Vemurafenib—skin cancer	0.063	0.0896	CbGbCtD
Iloperidone—CYP3A4—Temozolomide—skin cancer	0.0602	0.0857	CbGbCtD
Iloperidone—CYP3A4—Imiquimod—skin cancer	0.0602	0.0857	CbGbCtD
Iloperidone—CYP2D6—Vemurafenib—skin cancer	0.0519	0.0738	CbGbCtD
Iloperidone—CYP1A2—Dacarbazine—skin cancer	0.0483	0.0687	CbGbCtD
Iloperidone—CYP3A4—Vismodegib—skin cancer	0.0417	0.0594	CbGbCtD
Iloperidone—CYP3A7-CYP3A51P—Docetaxel—skin cancer	0.0387	0.0551	CbGbCtD
Iloperidone—CYP3A7—Docetaxel—skin cancer	0.0387	0.0551	CbGbCtD
Iloperidone—CYP3A4—Vemurafenib—skin cancer	0.033	0.047	CbGbCtD
Iloperidone—CYP3A5—Docetaxel—skin cancer	0.029	0.0413	CbGbCtD
Iloperidone—CYP1A2—Fluorouracil—skin cancer	0.0283	0.0403	CbGbCtD
Iloperidone—CYP3A4—Docetaxel—skin cancer	0.0113	0.0161	CbGbCtD
Iloperidone—HRH1—nose—skin cancer	0.00579	0.0961	CbGeAlD
Iloperidone—DRD1—nerve—skin cancer	0.00356	0.059	CbGeAlD
Iloperidone—HTR2A—hindlimb—skin cancer	0.00228	0.0378	CbGeAlD
Iloperidone—HTR7—nerve—skin cancer	0.00222	0.0369	CbGeAlD
Iloperidone—HTR1D—blood vessel—skin cancer	0.00219	0.0364	CbGeAlD
Iloperidone—DRD2—nerve—skin cancer	0.0021	0.0349	CbGeAlD
Iloperidone—HTR2A—appendage—skin cancer	0.00196	0.0325	CbGeAlD
Iloperidone—HTR7—endothelium—skin cancer	0.00189	0.0314	CbGeAlD
Iloperidone—HTR7—blood vessel—skin cancer	0.00175	0.029	CbGeAlD
Iloperidone—Arthralgia—Vismodegib—skin cancer	0.0015	0.00683	CcSEcCtD
Iloperidone—Myalgia—Vismodegib—skin cancer	0.0015	0.00683	CcSEcCtD
Iloperidone—SIGMAR1—nipple—skin cancer	0.00148	0.0245	CbGeAlD
Iloperidone—Urinary retention—Imiquimod—skin cancer	0.00146	0.00668	CcSEcCtD
Iloperidone—Breast pain—Temozolomide—skin cancer	0.00146	0.00664	CcSEcCtD
Iloperidone—Amenorrhoea—Temozolomide—skin cancer	0.00145	0.0066	CcSEcCtD
Iloperidone—Weight decreased—Vemurafenib—skin cancer	0.00141	0.00644	CcSEcCtD
Iloperidone—Nervous system disorder—Vismodegib—skin cancer	0.00141	0.00642	CcSEcCtD
Iloperidone—Breast disorder—Imiquimod—skin cancer	0.00139	0.00635	CcSEcCtD
Iloperidone—HTR2A—nerve—skin cancer	0.00139	0.023	CbGeAlD
Iloperidone—Musculoskeletal discomfort—Vismodegib—skin cancer	0.00131	0.00597	CcSEcCtD
Iloperidone—Gait disturbance—Temozolomide—skin cancer	0.0013	0.00594	CcSEcCtD
Iloperidone—Mouth ulceration—Dactinomycin—skin cancer	0.00127	0.00579	CcSEcCtD
Iloperidone—HTR7—neck—skin cancer	0.00125	0.0207	CbGeAlD
Iloperidone—Dysuria—Imiquimod—skin cancer	0.00124	0.00567	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Vismodegib—skin cancer	0.00124	0.00566	CcSEcCtD
Iloperidone—Fatigue—Vismodegib—skin cancer	0.00124	0.00565	CcSEcCtD
Iloperidone—Upper respiratory tract infection—Imiquimod—skin cancer	0.00124	0.00564	CcSEcCtD
Iloperidone—Haemoglobin decreased—Docetaxel—skin cancer	0.00123	0.0056	CcSEcCtD
Iloperidone—Urinary incontinence—Temozolomide—skin cancer	0.00123	0.0056	CcSEcCtD
Iloperidone—Connective tissue disorder—Vemurafenib—skin cancer	0.00123	0.0056	CcSEcCtD
Iloperidone—Erectile dysfunction—Imiquimod—skin cancer	0.00123	0.00559	CcSEcCtD
Iloperidone—HTR2A—endothelium—skin cancer	0.00118	0.0196	CbGeAlD
Iloperidone—DRD3—head—skin cancer	0.00118	0.0196	CbGeAlD
Iloperidone—Dry eye—Temozolomide—skin cancer	0.00117	0.00535	CcSEcCtD
Iloperidone—Eye disorder—Vemurafenib—skin cancer	0.00117	0.00532	CcSEcCtD
Iloperidone—ADRA2C—nipple—skin cancer	0.00116	0.0192	CbGeAlD
Iloperidone—Cardiac disorder—Vemurafenib—skin cancer	0.00116	0.00529	CcSEcCtD
Iloperidone—Conjunctivitis—Imiquimod—skin cancer	0.00115	0.00526	CcSEcCtD
Iloperidone—HTR6—head—skin cancer	0.00113	0.0188	CbGeAlD
Iloperidone—Angiopathy—Vemurafenib—skin cancer	0.00113	0.00517	CcSEcCtD
Iloperidone—Mediastinal disorder—Vemurafenib—skin cancer	0.00113	0.00513	CcSEcCtD
Iloperidone—HTR1D—connective tissue—skin cancer	0.00112	0.0186	CbGeAlD
Iloperidone—Hepatobiliary disease—Imiquimod—skin cancer	0.00112	0.00512	CcSEcCtD
Iloperidone—HTR2A—blood vessel—skin cancer	0.00109	0.0181	CbGeAlD
Iloperidone—Malnutrition—Vemurafenib—skin cancer	0.00109	0.00496	CcSEcCtD
Iloperidone—Urinary tract disorder—Imiquimod—skin cancer	0.00105	0.0048	CcSEcCtD
Iloperidone—Connective tissue disorder—Imiquimod—skin cancer	0.00105	0.00477	CcSEcCtD
Iloperidone—Urethral disorder—Imiquimod—skin cancer	0.00104	0.00476	CcSEcCtD
Iloperidone—Rhinorrhoea—Docetaxel—skin cancer	0.00104	0.00476	CcSEcCtD
Iloperidone—Lethargy—Dactinomycin—skin cancer	0.00104	0.00475	CcSEcCtD
Iloperidone—Asthenia—Vismodegib—skin cancer	0.00103	0.0047	CcSEcCtD
Iloperidone—Nasal congestion—Temozolomide—skin cancer	0.00101	0.00462	CcSEcCtD
Iloperidone—CYP1A2—nipple—skin cancer	0.00101	0.0167	CbGeAlD
Iloperidone—Eye disorder—Imiquimod—skin cancer	0.000995	0.00454	CcSEcCtD
Iloperidone—Tinnitus—Imiquimod—skin cancer	0.000993	0.00453	CcSEcCtD
Iloperidone—Diarrhoea—Vismodegib—skin cancer	0.000983	0.00448	CcSEcCtD
Iloperidone—Amnesia—Temozolomide—skin cancer	0.000982	0.00448	CcSEcCtD
Iloperidone—Thirst—Temozolomide—skin cancer	0.00097	0.00442	CcSEcCtD
Iloperidone—Angiopathy—Imiquimod—skin cancer	0.000966	0.00441	CcSEcCtD
Iloperidone—Amenorrhoea—Docetaxel—skin cancer	0.000962	0.00439	CcSEcCtD
Iloperidone—Mediastinal disorder—Imiquimod—skin cancer	0.00096	0.00438	CcSEcCtD
Iloperidone—Arrhythmia—Imiquimod—skin cancer	0.000952	0.00434	CcSEcCtD
Iloperidone—HRH1—nipple—skin cancer	0.000943	0.0156	CbGeAlD
Iloperidone—Mental disorder—Imiquimod—skin cancer	0.000933	0.00426	CcSEcCtD
Iloperidone—Malnutrition—Imiquimod—skin cancer	0.000927	0.00423	CcSEcCtD
Iloperidone—ADRA2A—nipple—skin cancer	0.000926	0.0154	CbGeAlD
Iloperidone—Arthralgia—Vemurafenib—skin cancer	0.000926	0.00422	CcSEcCtD
Iloperidone—Myalgia—Vemurafenib—skin cancer	0.000926	0.00422	CcSEcCtD
Iloperidone—Affect lability—Temozolomide—skin cancer	0.000908	0.00414	CcSEcCtD
Iloperidone—Rash—Vismodegib—skin cancer	0.000906	0.00413	CcSEcCtD
Iloperidone—Amnesia—Fluorouracil—skin cancer	0.000905	0.00413	CcSEcCtD
Iloperidone—Dermatitis—Vismodegib—skin cancer	0.000905	0.00413	CcSEcCtD
Iloperidone—HTR7—connective tissue—skin cancer	0.000895	0.0149	CbGeAlD
Iloperidone—Infection—Vemurafenib—skin cancer	0.000882	0.00402	CcSEcCtD
Iloperidone—Mood swings—Temozolomide—skin cancer	0.000874	0.00399	CcSEcCtD
Iloperidone—Cardiac failure—Fluorouracil—skin cancer	0.000871	0.00397	CcSEcCtD
Iloperidone—Nervous system disorder—Vemurafenib—skin cancer	0.00087	0.00397	CcSEcCtD
Iloperidone—Lethargy—Fluorouracil—skin cancer	0.000868	0.00396	CcSEcCtD
Iloperidone—SIGMAR1—mammalian vulva—skin cancer	0.000863	0.0143	CbGeAlD
Iloperidone—Dehydration—Temozolomide—skin cancer	0.000858	0.00391	CcSEcCtD
Iloperidone—Weight decreased—Bleomycin—skin cancer	0.000855	0.0039	CcSEcCtD
Iloperidone—Nausea—Vismodegib—skin cancer	0.000853	0.00389	CcSEcCtD
Iloperidone—Agitation—Imiquimod—skin cancer	0.000852	0.00389	CcSEcCtD
Iloperidone—HTR7—epithelium—skin cancer	0.00085	0.0141	CbGeAlD
Iloperidone—DRD1—head—skin cancer	0.000844	0.014	CbGeAlD
Iloperidone—Hypokalaemia—Temozolomide—skin cancer	0.00084	0.00383	CcSEcCtD
Iloperidone—Breast disorder—Temozolomide—skin cancer	0.000834	0.0038	CcSEcCtD
Iloperidone—Hypotension—Vemurafenib—skin cancer	0.000829	0.00378	CcSEcCtD
Iloperidone—Stomatitis—Bleomycin—skin cancer	0.000822	0.00375	CcSEcCtD
Iloperidone—ADRA1A—epithelium—skin cancer	0.00082	0.0136	CbGeAlD
Iloperidone—Palpitations—Imiquimod—skin cancer	0.000819	0.00374	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.000808	0.00369	CcSEcCtD
Iloperidone—Fluid retention—Docetaxel—skin cancer	0.000802	0.00366	CcSEcCtD
Iloperidone—HTR1D—female reproductive system—skin cancer	0.000793	0.0132	CbGeAlD
Iloperidone—Myalgia—Imiquimod—skin cancer	0.000789	0.0036	CcSEcCtD
Iloperidone—Arthralgia—Imiquimod—skin cancer	0.000789	0.0036	CcSEcCtD
Iloperidone—HTR2C—female reproductive system—skin cancer	0.000785	0.013	CbGeAlD
Iloperidone—HTR2A—neck—skin cancer	0.000779	0.0129	CbGeAlD
Iloperidone—Dry mouth—Imiquimod—skin cancer	0.000772	0.00352	CcSEcCtD
Iloperidone—Stomatitis—Dactinomycin—skin cancer	0.000766	0.00349	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Vemurafenib—skin cancer	0.000766	0.00349	CcSEcCtD
Iloperidone—Fatigue—Vemurafenib—skin cancer	0.000765	0.00349	CcSEcCtD
Iloperidone—Nasopharyngitis—Fluorouracil—skin cancer	0.00076	0.00347	CcSEcCtD
Iloperidone—Oedema—Imiquimod—skin cancer	0.000757	0.00345	CcSEcCtD
Iloperidone—Infection—Imiquimod—skin cancer	0.000752	0.00343	CcSEcCtD
Iloperidone—Dysuria—Temozolomide—skin cancer	0.000746	0.0034	CcSEcCtD
Iloperidone—Nervous system disorder—Imiquimod—skin cancer	0.000742	0.00338	CcSEcCtD
Iloperidone—Upper respiratory tract infection—Temozolomide—skin cancer	0.000741	0.00338	CcSEcCtD
Iloperidone—Tachycardia—Imiquimod—skin cancer	0.000739	0.00337	CcSEcCtD
Iloperidone—Pollakiuria—Temozolomide—skin cancer	0.000737	0.00336	CcSEcCtD
Iloperidone—Erectile dysfunction—Temozolomide—skin cancer	0.000734	0.00335	CcSEcCtD
Iloperidone—Weight increased—Temozolomide—skin cancer	0.000726	0.00331	CcSEcCtD
Iloperidone—Weight decreased—Temozolomide—skin cancer	0.000721	0.00329	CcSEcCtD
Iloperidone—Body temperature increased—Vemurafenib—skin cancer	0.000701	0.0032	CcSEcCtD
Iloperidone—Stomatitis—Temozolomide—skin cancer	0.000693	0.00316	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Imiquimod—skin cancer	0.000689	0.00314	CcSEcCtD
Iloperidone—Upper respiratory tract infection—Fluorouracil—skin cancer	0.000683	0.00311	CcSEcCtD
Iloperidone—Paraesthesia—Imiquimod—skin cancer	0.00068	0.0031	CcSEcCtD
Iloperidone—ADRA2C—mammalian vulva—skin cancer	0.000678	0.0112	CbGeAlD
Iloperidone—Dyspnoea—Imiquimod—skin cancer	0.000675	0.00308	CcSEcCtD
Iloperidone—Somnolence—Imiquimod—skin cancer	0.000673	0.00307	CcSEcCtD
Iloperidone—Hepatobiliary disease—Temozolomide—skin cancer	0.000672	0.00307	CcSEcCtD
Iloperidone—HRH1—connective tissue—skin cancer	0.000668	0.0111	CbGeAlD
Iloperidone—HTR1D—head—skin cancer	0.000662	0.011	CbGeAlD
Iloperidone—ADRA2A—connective tissue—skin cancer	0.000657	0.0109	CbGeAlD
Iloperidone—HTR2C—head—skin cancer	0.000656	0.0109	CbGeAlD
Iloperidone—Gastrointestinal disorder—Imiquimod—skin cancer	0.000653	0.00298	CcSEcCtD
Iloperidone—Fatigue—Imiquimod—skin cancer	0.000652	0.00298	CcSEcCtD
Iloperidone—Stomatitis—Fluorouracil—skin cancer	0.000639	0.00291	CcSEcCtD
Iloperidone—Conjunctivitis—Fluorouracil—skin cancer	0.000637	0.0029	CcSEcCtD
Iloperidone—Asthenia—Vemurafenib—skin cancer	0.000637	0.0029	CcSEcCtD
Iloperidone—HRH1—epithelium—skin cancer	0.000635	0.0105	CbGeAlD
Iloperidone—ADRA1A—lymphoid tissue—skin cancer	0.000631	0.0105	CbGeAlD
Iloperidone—HTR7—female reproductive system—skin cancer	0.000631	0.0105	CbGeAlD
Iloperidone—Urinary tract disorder—Temozolomide—skin cancer	0.00063	0.00287	CcSEcCtD
Iloperidone—Cardiac failure—Docetaxel—skin cancer	0.000629	0.00287	CcSEcCtD
Iloperidone—Connective tissue disorder—Temozolomide—skin cancer	0.000627	0.00286	CcSEcCtD
Iloperidone—Lethargy—Docetaxel—skin cancer	0.000626	0.00286	CcSEcCtD
Iloperidone—Urethral disorder—Temozolomide—skin cancer	0.000626	0.00285	CcSEcCtD
Iloperidone—Feeling abnormal—Imiquimod—skin cancer	0.000624	0.00284	CcSEcCtD
Iloperidone—Epistaxis—Fluorouracil—skin cancer	0.000618	0.00282	CcSEcCtD
Iloperidone—Anaemia—Bleomycin—skin cancer	0.000609	0.00278	CcSEcCtD
Iloperidone—Diarrhoea—Vemurafenib—skin cancer	0.000607	0.00277	CcSEcCtD
Iloperidone—Body temperature increased—Imiquimod—skin cancer	0.000598	0.00273	CcSEcCtD
Iloperidone—Eye disorder—Temozolomide—skin cancer	0.000597	0.00272	CcSEcCtD
Iloperidone—Tinnitus—Temozolomide—skin cancer	0.000595	0.00271	CcSEcCtD
Iloperidone—Cardiac disorder—Temozolomide—skin cancer	0.000592	0.0027	CcSEcCtD
Iloperidone—Leukopenia—Bleomycin—skin cancer	0.00059	0.00269	CcSEcCtD
Iloperidone—Dizziness—Vemurafenib—skin cancer	0.000587	0.00268	CcSEcCtD
Iloperidone—Angiopathy—Temozolomide—skin cancer	0.000579	0.00264	CcSEcCtD
Iloperidone—Mediastinal disorder—Temozolomide—skin cancer	0.000575	0.00262	CcSEcCtD
Iloperidone—Dehydration—Docetaxel—skin cancer	0.000571	0.0026	CcSEcCtD
Iloperidone—Anaemia—Dactinomycin—skin cancer	0.000568	0.00259	CcSEcCtD
Iloperidone—Myalgia—Bleomycin—skin cancer	0.000561	0.00256	CcSEcCtD
Iloperidone—Orthostatic hypotension—Docetaxel—skin cancer	0.00056	0.00256	CcSEcCtD
Iloperidone—Rash—Vemurafenib—skin cancer	0.000559	0.00255	CcSEcCtD
Iloperidone—Mental disorder—Temozolomide—skin cancer	0.000559	0.00255	CcSEcCtD
Iloperidone—Dermatitis—Vemurafenib—skin cancer	0.000559	0.00255	CcSEcCtD
Iloperidone—HTR2A—connective tissue—skin cancer	0.000558	0.00926	CbGeAlD
Iloperidone—Malnutrition—Temozolomide—skin cancer	0.000556	0.00253	CcSEcCtD
Iloperidone—Breast disorder—Docetaxel—skin cancer	0.000554	0.00253	CcSEcCtD
Iloperidone—HTR1A—head—skin cancer	0.000552	0.00916	CbGeAlD
Iloperidone—HRH1—mammalian vulva—skin cancer	0.000551	0.00913	CbGeAlD
Iloperidone—Leukopenia—Dactinomycin—skin cancer	0.00055	0.00251	CcSEcCtD
Iloperidone—Nasopharyngitis—Docetaxel—skin cancer	0.000549	0.0025	CcSEcCtD
Iloperidone—Asthenia—Imiquimod—skin cancer	0.000543	0.00248	CcSEcCtD
Iloperidone—Confusional state—Bleomycin—skin cancer	0.000542	0.00247	CcSEcCtD
Iloperidone—ADRA2A—mammalian vulva—skin cancer	0.000541	0.00897	CbGeAlD
Iloperidone—Oedema—Bleomycin—skin cancer	0.000538	0.00245	CcSEcCtD
Iloperidone—Infection—Bleomycin—skin cancer	0.000534	0.00244	CcSEcCtD
Iloperidone—HTR2A—epithelium—skin cancer	0.00053	0.00879	CbGeAlD
Iloperidone—HTR7—head—skin cancer	0.000528	0.00875	CbGeAlD
Iloperidone—Nausea—Vemurafenib—skin cancer	0.000527	0.0024	CcSEcCtD
Iloperidone—Arrhythmia—Fluorouracil—skin cancer	0.000525	0.0024	CcSEcCtD
Iloperidone—Vision blurred—Temozolomide—skin cancer	0.000524	0.00239	CcSEcCtD
Iloperidone—Myalgia—Dactinomycin—skin cancer	0.000523	0.00239	CcSEcCtD
Iloperidone—Tremor—Temozolomide—skin cancer	0.000521	0.00237	CcSEcCtD
Iloperidone—Diarrhoea—Imiquimod—skin cancer	0.000518	0.00236	CcSEcCtD
Iloperidone—Anaemia—Temozolomide—skin cancer	0.000514	0.00234	CcSEcCtD
Iloperidone—Agitation—Temozolomide—skin cancer	0.000511	0.00233	CcSEcCtD
Iloperidone—ADRA1A—head—skin cancer	0.000509	0.00844	CbGeAlD
Iloperidone—Hypotension—Bleomycin—skin cancer	0.000502	0.00229	CcSEcCtD
Iloperidone—Oedema—Dactinomycin—skin cancer	0.000501	0.00229	CcSEcCtD
Iloperidone—Dizziness—Imiquimod—skin cancer	0.0005	0.00228	CcSEcCtD
Iloperidone—Vertigo—Temozolomide—skin cancer	0.000499	0.00228	CcSEcCtD
Iloperidone—DRD2—head—skin cancer	0.000499	0.00827	CbGeAlD
Iloperidone—Infection—Dactinomycin—skin cancer	0.000498	0.00227	CcSEcCtD
Iloperidone—Leukopenia—Temozolomide—skin cancer	0.000497	0.00227	CcSEcCtD
Iloperidone—Palpitations—Temozolomide—skin cancer	0.000491	0.00224	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Bleomycin—skin cancer	0.00049	0.00223	CcSEcCtD
Iloperidone—ADRA2C—head—skin cancer	0.000485	0.00804	CbGeAlD
Iloperidone—Paraesthesia—Bleomycin—skin cancer	0.000483	0.0022	CcSEcCtD
Iloperidone—Weight increased—Docetaxel—skin cancer	0.000483	0.0022	CcSEcCtD
Iloperidone—Vision blurred—Fluorouracil—skin cancer	0.000483	0.0022	CcSEcCtD
Iloperidone—Weight decreased—Docetaxel—skin cancer	0.00048	0.00219	CcSEcCtD
Iloperidone—Dyspnoea—Bleomycin—skin cancer	0.000479	0.00219	CcSEcCtD
Iloperidone—Rash—Imiquimod—skin cancer	0.000477	0.00218	CcSEcCtD
Iloperidone—Dermatitis—Imiquimod—skin cancer	0.000477	0.00217	CcSEcCtD
Iloperidone—Anaemia—Fluorouracil—skin cancer	0.000473	0.00216	CcSEcCtD
Iloperidone—Myalgia—Temozolomide—skin cancer	0.000473	0.00216	CcSEcCtD
Iloperidone—Arthralgia—Temozolomide—skin cancer	0.000473	0.00216	CcSEcCtD
Iloperidone—HRH1—female reproductive system—skin cancer	0.000471	0.00782	CbGeAlD
Iloperidone—CYP2E1—lymphoid tissue—skin cancer	0.00047	0.00779	CbGeAlD
Iloperidone—ADRA2A—female reproductive system—skin cancer	0.000463	0.00768	CbGeAlD
Iloperidone—Dry mouth—Temozolomide—skin cancer	0.000463	0.00211	CcSEcCtD
Iloperidone—Stomatitis—Docetaxel—skin cancer	0.000461	0.0021	CcSEcCtD
Iloperidone—Conjunctivitis—Docetaxel—skin cancer	0.00046	0.0021	CcSEcCtD
Iloperidone—Leukopenia—Fluorouracil—skin cancer	0.000458	0.00209	CcSEcCtD
Iloperidone—Confusional state—Temozolomide—skin cancer	0.000457	0.00209	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000457	0.00208	CcSEcCtD
Iloperidone—Oedema—Temozolomide—skin cancer	0.000453	0.00207	CcSEcCtD
Iloperidone—CYP2E1—female reproductive system—skin cancer	0.000453	0.00752	CbGeAlD
Iloperidone—Infection—Temozolomide—skin cancer	0.000451	0.00205	CcSEcCtD
Iloperidone—Nausea—Imiquimod—skin cancer	0.000449	0.00205	CcSEcCtD
Iloperidone—Hepatobiliary disease—Docetaxel—skin cancer	0.000447	0.00204	CcSEcCtD
Iloperidone—Epistaxis—Docetaxel—skin cancer	0.000446	0.00203	CcSEcCtD
Iloperidone—Nervous system disorder—Temozolomide—skin cancer	0.000445	0.00203	CcSEcCtD
Iloperidone—Feeling abnormal—Bleomycin—skin cancer	0.000443	0.00202	CcSEcCtD
Iloperidone—Myalgia—Fluorouracil—skin cancer	0.000436	0.00199	CcSEcCtD
Iloperidone—SIGMAR1—lymph node—skin cancer	0.000432	0.00717	CbGeAlD
Iloperidone—Fatigue—Dactinomycin—skin cancer	0.000432	0.00197	CcSEcCtD
Iloperidone—Body temperature increased—Bleomycin—skin cancer	0.000425	0.00194	CcSEcCtD
Iloperidone—Confusional state—Fluorouracil—skin cancer	0.000421	0.00192	CcSEcCtD
Iloperidone—Urinary tract disorder—Docetaxel—skin cancer	0.000419	0.00191	CcSEcCtD
Iloperidone—Oedema—Fluorouracil—skin cancer	0.000418	0.00191	CcSEcCtD
Iloperidone—Connective tissue disorder—Docetaxel—skin cancer	0.000417	0.0019	CcSEcCtD
Iloperidone—Urethral disorder—Docetaxel—skin cancer	0.000416	0.0019	CcSEcCtD
Iloperidone—Infection—Fluorouracil—skin cancer	0.000415	0.00189	CcSEcCtD
Iloperidone—Feeling abnormal—Dactinomycin—skin cancer	0.000413	0.00188	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000413	0.00188	CcSEcCtD
Iloperidone—Nervous system disorder—Fluorouracil—skin cancer	0.00041	0.00187	CcSEcCtD
Iloperidone—Tachycardia—Fluorouracil—skin cancer	0.000408	0.00186	CcSEcCtD
Iloperidone—Paraesthesia—Temozolomide—skin cancer	0.000407	0.00186	CcSEcCtD
Iloperidone—Dyspnoea—Temozolomide—skin cancer	0.000404	0.00184	CcSEcCtD
Iloperidone—Somnolence—Temozolomide—skin cancer	0.000403	0.00184	CcSEcCtD
Iloperidone—Eye disorder—Docetaxel—skin cancer	0.000397	0.00181	CcSEcCtD
Iloperidone—Body temperature increased—Dactinomycin—skin cancer	0.000396	0.00181	CcSEcCtD
Iloperidone—Cardiac disorder—Docetaxel—skin cancer	0.000394	0.0018	CcSEcCtD
Iloperidone—HRH1—head—skin cancer	0.000394	0.00653	CbGeAlD
Iloperidone—HTR2A—female reproductive system—skin cancer	0.000394	0.00653	CbGeAlD
Iloperidone—Gastrointestinal disorder—Temozolomide—skin cancer	0.000392	0.00179	CcSEcCtD
Iloperidone—Fatigue—Temozolomide—skin cancer	0.000391	0.00178	CcSEcCtD
Iloperidone—Hypotension—Fluorouracil—skin cancer	0.00039	0.00178	CcSEcCtD
Iloperidone—ADRA2A—head—skin cancer	0.000387	0.00642	CbGeAlD
Iloperidone—Asthenia—Bleomycin—skin cancer	0.000386	0.00176	CcSEcCtD
Iloperidone—Angiopathy—Docetaxel—skin cancer	0.000385	0.00176	CcSEcCtD
Iloperidone—Mediastinal disorder—Docetaxel—skin cancer	0.000383	0.00174	CcSEcCtD
Iloperidone—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000381	0.00174	CcSEcCtD
Iloperidone—Arrhythmia—Docetaxel—skin cancer	0.000379	0.00173	CcSEcCtD
Iloperidone—CYP2E1—head—skin cancer	0.000378	0.00628	CbGeAlD
Iloperidone—Paraesthesia—Fluorouracil—skin cancer	0.000375	0.00171	CcSEcCtD
Iloperidone—Feeling abnormal—Temozolomide—skin cancer	0.000374	0.0017	CcSEcCtD
Iloperidone—Dyspnoea—Fluorouracil—skin cancer	0.000373	0.0017	CcSEcCtD
Iloperidone—Mental disorder—Docetaxel—skin cancer	0.000372	0.0017	CcSEcCtD
Iloperidone—Somnolence—Fluorouracil—skin cancer	0.000371	0.00169	CcSEcCtD
Iloperidone—Malnutrition—Docetaxel—skin cancer	0.00037	0.00169	CcSEcCtD
Iloperidone—CYP3A4—female reproductive system—skin cancer	0.000365	0.00605	CbGeAlD
Iloperidone—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000361	0.00165	CcSEcCtD
Iloperidone—Asthenia—Dactinomycin—skin cancer	0.00036	0.00164	CcSEcCtD
Iloperidone—CYP2D6—female reproductive system—skin cancer	0.000359	0.00595	CbGeAlD
Iloperidone—Body temperature increased—Temozolomide—skin cancer	0.000358	0.00163	CcSEcCtD
Iloperidone—Muscle spasms—Docetaxel—skin cancer	0.000355	0.00162	CcSEcCtD
Iloperidone—Feeling abnormal—Fluorouracil—skin cancer	0.000344	0.00157	CcSEcCtD
Iloperidone—Diarrhoea—Dactinomycin—skin cancer	0.000343	0.00156	CcSEcCtD
Iloperidone—Anaemia—Docetaxel—skin cancer	0.000342	0.00156	CcSEcCtD
Iloperidone—ADRA2C—lymph node—skin cancer	0.000339	0.00563	CbGeAlD
Iloperidone—Rash—Bleomycin—skin cancer	0.000339	0.00155	CcSEcCtD
Iloperidone—Dermatitis—Bleomycin—skin cancer	0.000339	0.00154	CcSEcCtD
Iloperidone—Leukopenia—Docetaxel—skin cancer	0.000331	0.00151	CcSEcCtD
Iloperidone—Body temperature increased—Fluorouracil—skin cancer	0.00033	0.00151	CcSEcCtD
Iloperidone—HTR2A—head—skin cancer	0.000329	0.00546	CbGeAlD
Iloperidone—Palpitations—Docetaxel—skin cancer	0.000327	0.00149	CcSEcCtD
Iloperidone—Asthenia—Temozolomide—skin cancer	0.000325	0.00148	CcSEcCtD
Iloperidone—Nausea—Bleomycin—skin cancer	0.000319	0.00146	CcSEcCtD
Iloperidone—Rash—Dactinomycin—skin cancer	0.000316	0.00144	CcSEcCtD
Iloperidone—Arthralgia—Docetaxel—skin cancer	0.000315	0.00143	CcSEcCtD
Iloperidone—Myalgia—Docetaxel—skin cancer	0.000315	0.00143	CcSEcCtD
Iloperidone—Diarrhoea—Temozolomide—skin cancer	0.00031	0.00142	CcSEcCtD
Iloperidone—Dry mouth—Docetaxel—skin cancer	0.000308	0.0014	CcSEcCtD
Iloperidone—Confusional state—Docetaxel—skin cancer	0.000304	0.00139	CcSEcCtD
Iloperidone—Oedema—Docetaxel—skin cancer	0.000302	0.00138	CcSEcCtD
Iloperidone—Dizziness—Temozolomide—skin cancer	0.0003	0.00137	CcSEcCtD
Iloperidone—CYP2D6—head—skin cancer	0.0003	0.00497	CbGeAlD
Iloperidone—Infection—Docetaxel—skin cancer	0.0003	0.00137	CcSEcCtD
Iloperidone—Nausea—Dactinomycin—skin cancer	0.000298	0.00136	CcSEcCtD
Iloperidone—Nervous system disorder—Docetaxel—skin cancer	0.000296	0.00135	CcSEcCtD
Iloperidone—Tachycardia—Docetaxel—skin cancer	0.000294	0.00134	CcSEcCtD
Iloperidone—Rash—Temozolomide—skin cancer	0.000286	0.0013	CcSEcCtD
Iloperidone—Diarrhoea—Fluorouracil—skin cancer	0.000286	0.0013	CcSEcCtD
Iloperidone—Dermatitis—Temozolomide—skin cancer	0.000286	0.0013	CcSEcCtD
Iloperidone—Hypotension—Docetaxel—skin cancer	0.000282	0.00129	CcSEcCtD
Iloperidone—Dizziness—Fluorouracil—skin cancer	0.000276	0.00126	CcSEcCtD
Iloperidone—HRH1—lymph node—skin cancer	0.000276	0.00458	CbGeAlD
Iloperidone—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000275	0.00125	CcSEcCtD
Iloperidone—ADRA2A—lymph node—skin cancer	0.000271	0.00449	CbGeAlD
Iloperidone—Paraesthesia—Docetaxel—skin cancer	0.000271	0.00124	CcSEcCtD
Iloperidone—Nausea—Temozolomide—skin cancer	0.000269	0.00123	CcSEcCtD
Iloperidone—Dyspnoea—Docetaxel—skin cancer	0.000269	0.00123	CcSEcCtD
Iloperidone—Somnolence—Docetaxel—skin cancer	0.000268	0.00122	CcSEcCtD
Iloperidone—Rash—Fluorouracil—skin cancer	0.000263	0.0012	CcSEcCtD
Iloperidone—Dermatitis—Fluorouracil—skin cancer	0.000263	0.0012	CcSEcCtD
Iloperidone—Gastrointestinal disorder—Docetaxel—skin cancer	0.00026	0.00119	CcSEcCtD
Iloperidone—Fatigue—Docetaxel—skin cancer	0.00026	0.00119	CcSEcCtD
Iloperidone—Feeling abnormal—Docetaxel—skin cancer	0.000249	0.00113	CcSEcCtD
Iloperidone—Nausea—Fluorouracil—skin cancer	0.000248	0.00113	CcSEcCtD
Iloperidone—Body temperature increased—Docetaxel—skin cancer	0.000238	0.00109	CcSEcCtD
Iloperidone—Asthenia—Docetaxel—skin cancer	0.000216	0.000987	CcSEcCtD
Iloperidone—Diarrhoea—Docetaxel—skin cancer	0.000206	0.000941	CcSEcCtD
Iloperidone—Dizziness—Docetaxel—skin cancer	0.000199	0.00091	CcSEcCtD
Iloperidone—Rash—Docetaxel—skin cancer	0.00019	0.000867	CcSEcCtD
Iloperidone—Dermatitis—Docetaxel—skin cancer	0.00019	0.000866	CcSEcCtD
Iloperidone—Nausea—Docetaxel—skin cancer	0.000179	0.000817	CcSEcCtD
Iloperidone—DRD3—Signaling Pathways—PTGER4—skin cancer	1.15e-05	0.00065	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—FOXO4—skin cancer	1.15e-05	0.000646	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—SUFU—skin cancer	1.12e-05	0.000633	CbGpPWpGaD
Iloperidone—DRD2—Circadian rythm related genes—IL6—skin cancer	1.12e-05	0.000631	CbGpPWpGaD
Iloperidone—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	1.09e-05	0.000615	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—SHH—skin cancer	1.09e-05	0.000614	CbGpPWpGaD
Iloperidone—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	1.09e-05	0.000614	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—SHH—skin cancer	1.08e-05	0.000611	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—RASA1—skin cancer	1.08e-05	0.00061	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—RASA1—skin cancer	1.08e-05	0.000607	CbGpPWpGaD
Iloperidone—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	1.07e-05	0.000602	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—SHH—skin cancer	1.05e-05	0.000594	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—RASA1—skin cancer	1.05e-05	0.00059	CbGpPWpGaD
Iloperidone—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	1.04e-05	0.000589	CbGpPWpGaD
Iloperidone—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	1.04e-05	0.000587	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—FOXO4—skin cancer	1.03e-05	0.000582	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—SMO—skin cancer	1.03e-05	0.000582	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—PTCH1—skin cancer	1.03e-05	0.000582	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—PLIN2—skin cancer	1.03e-05	0.000581	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—PTCH1—skin cancer	1.03e-05	0.000579	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—SMO—skin cancer	1.03e-05	0.000579	CbGpPWpGaD
Iloperidone—ADRA2A—Metabolism—ENO2—skin cancer	1.02e-05	0.000577	CbGpPWpGaD
Iloperidone—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	1.02e-05	0.000576	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—FOXO4—skin cancer	1.02e-05	0.000574	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—PTGER4—skin cancer	1e-05	0.000566	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—PTGER4—skin cancer	9.99e-06	0.000564	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—PTCH1—skin cancer	9.98e-06	0.000563	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—SMO—skin cancer	9.98e-06	0.000563	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—CSPG4—skin cancer	9.81e-06	0.000553	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—PTGER4—skin cancer	9.72e-06	0.000548	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—SHH—skin cancer	9.55e-06	0.000539	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—RASA1—skin cancer	9.49e-06	0.000536	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—SHH—skin cancer	9.4e-06	0.00053	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—ENO2—skin cancer	9.39e-06	0.00053	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—SHH—skin cancer	9.38e-06	0.000529	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—ENO2—skin cancer	9.37e-06	0.000529	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—RASA1—skin cancer	9.34e-06	0.000527	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—RASA1—skin cancer	9.32e-06	0.000526	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—SHH—skin cancer	9.21e-06	0.000519	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—RASA1—skin cancer	9.15e-06	0.000516	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—SMO—skin cancer	9.06e-06	0.000511	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—PTCH1—skin cancer	9.06e-06	0.000511	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—SMO—skin cancer	8.91e-06	0.000503	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—PTCH1—skin cancer	8.91e-06	0.000503	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—PTCH1—skin cancer	8.89e-06	0.000502	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—SMO—skin cancer	8.89e-06	0.000502	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—FOXO4—skin cancer	8.87e-06	0.0005	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—FOXO4—skin cancer	8.83e-06	0.000498	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—PTGER4—skin cancer	8.82e-06	0.000497	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—PTCH1—skin cancer	8.73e-06	0.000492	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—SMO—skin cancer	8.73e-06	0.000492	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—PTGER4—skin cancer	8.68e-06	0.000489	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—PTGER4—skin cancer	8.66e-06	0.000488	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—FOXO4—skin cancer	8.58e-06	0.000484	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—SHH—skin cancer	8.55e-06	0.000482	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—RASA1—skin cancer	8.5e-06	0.000479	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—PTGER4—skin cancer	8.5e-06	0.000479	CbGpPWpGaD
Iloperidone—ADRA2C—Hemostasis—NRAS—skin cancer	8.42e-06	0.000475	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—CSPG4—skin cancer	8.31e-06	0.000469	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—PTCH1—skin cancer	8.11e-06	0.000457	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—SMO—skin cancer	8.11e-06	0.000457	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—TERT—skin cancer	8e-06	0.000452	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—TERT—skin cancer	8e-06	0.000451	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PLIN2—skin cancer	7.95e-06	0.000449	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—TERT—skin cancer	7.94e-06	0.000448	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—PTGER4—skin cancer	7.89e-06	0.000445	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—FOXO4—skin cancer	7.79e-06	0.000439	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—FOXO4—skin cancer	7.66e-06	0.000432	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—TERT—skin cancer	7.65e-06	0.000432	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—FOXO4—skin cancer	7.65e-06	0.000431	CbGpPWpGaD
Iloperidone—CYP3A7—Metabolism—ERCC2—skin cancer	7.53e-06	0.000425	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—FOXO4—skin cancer	7.5e-06	0.000423	CbGpPWpGaD
Iloperidone—ADRA2C—Metabolism—ERCC2—skin cancer	7.31e-06	0.000413	CbGpPWpGaD
Iloperidone—ADRA2C—Hemostasis—KRAS—skin cancer	7.24e-06	0.000409	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—FOXO4—skin cancer	6.97e-06	0.000393	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—TERT—skin cancer	6.89e-06	0.000389	CbGpPWpGaD
Iloperidone—ADRA2A—Hemostasis—NRAS—skin cancer	6.84e-06	0.000386	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—TERT—skin cancer	6.8e-06	0.000383	CbGpPWpGaD
Iloperidone—HTR6—Signaling by GPCR—NRAS—skin cancer	6.74e-06	0.00038	CbGpPWpGaD
Iloperidone—HTR7—Signaling by GPCR—NRAS—skin cancer	6.74e-06	0.00038	CbGpPWpGaD
Iloperidone—HTR1D—Signaling by GPCR—NRAS—skin cancer	6.69e-06	0.000378	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—ENO2—skin cancer	6.67e-06	0.000376	CbGpPWpGaD
Iloperidone—DRD4—Signaling by GPCR—NRAS—skin cancer	6.45e-06	0.000364	CbGpPWpGaD
Iloperidone—ADRA2C—Hemostasis—TP53—skin cancer	6.44e-06	0.000363	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—CSPG4—skin cancer	6.41e-06	0.000362	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—BRAF—skin cancer	6.34e-06	0.000358	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—BRAF—skin cancer	6.33e-06	0.000357	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—BRAF—skin cancer	6.29e-06	0.000355	CbGpPWpGaD
Iloperidone—ADRA2C—Hemostasis—HRAS—skin cancer	6.16e-06	0.000347	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—BRAF—skin cancer	6.06e-06	0.000342	CbGpPWpGaD
Iloperidone—ADRA2A—Metabolism—ERCC2—skin cancer	5.94e-06	0.000335	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—TERT—skin cancer	5.93e-06	0.000334	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—TERT—skin cancer	5.89e-06	0.000333	CbGpPWpGaD
Iloperidone—ADRA2A—Hemostasis—KRAS—skin cancer	5.88e-06	0.000332	CbGpPWpGaD
Iloperidone—DRD1—Signaling by GPCR—NRAS—skin cancer	5.81e-06	0.000327	CbGpPWpGaD
Iloperidone—HTR6—Signaling by GPCR—KRAS—skin cancer	5.8e-06	0.000327	CbGpPWpGaD
Iloperidone—HTR7—Signaling by GPCR—KRAS—skin cancer	5.8e-06	0.000327	CbGpPWpGaD
Iloperidone—HTR1D—Signaling by GPCR—KRAS—skin cancer	5.76e-06	0.000325	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—TERT—skin cancer	5.73e-06	0.000323	CbGpPWpGaD
Iloperidone—DRD3—Signaling by GPCR—NRAS—skin cancer	5.73e-06	0.000323	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—ENO2—skin cancer	5.65e-06	0.000319	CbGpPWpGaD
Iloperidone—DRD4—Signaling by GPCR—KRAS—skin cancer	5.55e-06	0.000313	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—BRAF—skin cancer	5.46e-06	0.000308	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—ERCC2—skin cancer	5.46e-06	0.000308	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—ERCC2—skin cancer	5.44e-06	0.000307	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—BRAF—skin cancer	5.38e-06	0.000304	CbGpPWpGaD
Iloperidone—ADRA2A—Hemostasis—TP53—skin cancer	5.23e-06	0.000295	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—TERT—skin cancer	5.2e-06	0.000293	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—TERT—skin cancer	5.12e-06	0.000289	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—TERT—skin cancer	5.11e-06	0.000288	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—TERT—skin cancer	5.01e-06	0.000283	CbGpPWpGaD
Iloperidone—ADRA2A—Hemostasis—HRAS—skin cancer	5e-06	0.000282	CbGpPWpGaD
Iloperidone—DRD1—Signaling by GPCR—KRAS—skin cancer	5e-06	0.000282	CbGpPWpGaD
Iloperidone—HTR1A—Signaling by GPCR—NRAS—skin cancer	4.99e-06	0.000282	CbGpPWpGaD
Iloperidone—HTR2C—Signaling by GPCR—NRAS—skin cancer	4.97e-06	0.00028	CbGpPWpGaD
Iloperidone—HTR6—Signaling by GPCR—HRAS—skin cancer	4.93e-06	0.000278	CbGpPWpGaD
Iloperidone—DRD3—Signaling by GPCR—KRAS—skin cancer	4.93e-06	0.000278	CbGpPWpGaD
Iloperidone—HTR7—Signaling by GPCR—HRAS—skin cancer	4.93e-06	0.000278	CbGpPWpGaD
Iloperidone—HTR1D—Signaling by GPCR—HRAS—skin cancer	4.9e-06	0.000276	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling by GPCR—NRAS—skin cancer	4.83e-06	0.000272	CbGpPWpGaD
Iloperidone—HTR6—Signaling by GPCR—IL6—skin cancer	4.72e-06	0.000266	CbGpPWpGaD
Iloperidone—DRD4—Signaling by GPCR—HRAS—skin cancer	4.72e-06	0.000266	CbGpPWpGaD
Iloperidone—HTR7—Signaling by GPCR—IL6—skin cancer	4.72e-06	0.000266	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—BRAF—skin cancer	4.69e-06	0.000265	CbGpPWpGaD
Iloperidone—HTR1D—Signaling by GPCR—IL6—skin cancer	4.69e-06	0.000264	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—BRAF—skin cancer	4.67e-06	0.000263	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—TERT—skin cancer	4.66e-06	0.000263	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—BRAF—skin cancer	4.54e-06	0.000256	CbGpPWpGaD
Iloperidone—CYP3A7—Metabolism—PTGS2—skin cancer	4.52e-06	0.000255	CbGpPWpGaD
Iloperidone—DRD4—Signaling by GPCR—IL6—skin cancer	4.52e-06	0.000255	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	4.42e-06	0.000249	CbGpPWpGaD
Iloperidone—ADRA2C—Metabolism—PTGS2—skin cancer	4.39e-06	0.000247	CbGpPWpGaD
Iloperidone—DRD2—Signaling by GPCR—NRAS—skin cancer	4.38e-06	0.000247	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—ENO2—skin cancer	4.36e-06	0.000246	CbGpPWpGaD
Iloperidone—HTR2A—Signaling by GPCR—NRAS—skin cancer	4.31e-06	0.000243	CbGpPWpGaD
Iloperidone—HRH1—Signaling by GPCR—NRAS—skin cancer	4.3e-06	0.000243	CbGpPWpGaD
Iloperidone—HTR1A—Signaling by GPCR—KRAS—skin cancer	4.3e-06	0.000242	CbGpPWpGaD
Iloperidone—HTR2C—Signaling by GPCR—KRAS—skin cancer	4.27e-06	0.000241	CbGpPWpGaD
Iloperidone—DRD1—Signaling by GPCR—HRAS—skin cancer	4.25e-06	0.00024	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling by GPCR—NRAS—skin cancer	4.22e-06	0.000238	CbGpPWpGaD
Iloperidone—DRD3—Signaling by GPCR—HRAS—skin cancer	4.19e-06	0.000236	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling by GPCR—KRAS—skin cancer	4.16e-06	0.000235	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—BRAF—skin cancer	4.12e-06	0.000232	CbGpPWpGaD
Iloperidone—DRD1—Signaling by GPCR—IL6—skin cancer	4.06e-06	0.000229	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—BRAF—skin cancer	4.05e-06	0.000229	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—BRAF—skin cancer	4.05e-06	0.000228	CbGpPWpGaD
Iloperidone—DRD3—Signaling by GPCR—IL6—skin cancer	4.01e-06	0.000226	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—NRAS—skin cancer	3.98e-06	0.000225	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—NRAS—skin cancer	3.98e-06	0.000224	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—BRAF—skin cancer	3.97e-06	0.000224	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—NRAS—skin cancer	3.95e-06	0.000223	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling by GPCR—NRAS—skin cancer	3.92e-06	0.000221	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—ERCC2—skin cancer	3.87e-06	0.000218	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—NRAS—skin cancer	3.81e-06	0.000215	CbGpPWpGaD
Iloperidone—DRD2—Signaling by GPCR—KRAS—skin cancer	3.77e-06	0.000213	CbGpPWpGaD
Iloperidone—HTR2A—Signaling by GPCR—KRAS—skin cancer	3.71e-06	0.000209	CbGpPWpGaD
Iloperidone—HRH1—Signaling by GPCR—KRAS—skin cancer	3.7e-06	0.000209	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—BRAF—skin cancer	3.69e-06	0.000208	CbGpPWpGaD
Iloperidone—HTR1A—Signaling by GPCR—HRAS—skin cancer	3.65e-06	0.000206	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling by GPCR—KRAS—skin cancer	3.63e-06	0.000205	CbGpPWpGaD
Iloperidone—HTR2C—Signaling by GPCR—HRAS—skin cancer	3.63e-06	0.000205	CbGpPWpGaD
Iloperidone—ADRA2A—Metabolism—PTGS2—skin cancer	3.56e-06	0.000201	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling by GPCR—HRAS—skin cancer	3.53e-06	0.000199	CbGpPWpGaD
Iloperidone—HTR1A—Signaling by GPCR—IL6—skin cancer	3.5e-06	0.000197	CbGpPWpGaD
Iloperidone—HTR2C—Signaling by GPCR—IL6—skin cancer	3.48e-06	0.000196	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—NRAS—skin cancer	3.43e-06	0.000193	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—KRAS—skin cancer	3.43e-06	0.000193	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—KRAS—skin cancer	3.43e-06	0.000193	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—KRAS—skin cancer	3.4e-06	0.000192	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—NRAS—skin cancer	3.38e-06	0.000191	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling by GPCR—IL6—skin cancer	3.38e-06	0.000191	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling by GPCR—KRAS—skin cancer	3.38e-06	0.00019	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—ERCC2—skin cancer	3.28e-06	0.000185	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—KRAS—skin cancer	3.28e-06	0.000185	CbGpPWpGaD
Iloperidone—CYP2E1—Metabolism—PTGS2—skin cancer	3.27e-06	0.000185	CbGpPWpGaD
Iloperidone—CYP3A5—Metabolism—PTGS2—skin cancer	3.26e-06	0.000184	CbGpPWpGaD
Iloperidone—DRD2—Signaling by GPCR—HRAS—skin cancer	3.21e-06	0.000181	CbGpPWpGaD
Iloperidone—HTR2A—Signaling by GPCR—HRAS—skin cancer	3.16e-06	0.000178	CbGpPWpGaD
Iloperidone—HRH1—Signaling by GPCR—HRAS—skin cancer	3.15e-06	0.000178	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling by GPCR—HRAS—skin cancer	3.09e-06	0.000174	CbGpPWpGaD
Iloperidone—DRD2—Signaling by GPCR—IL6—skin cancer	3.07e-06	0.000173	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—TP53—skin cancer	3.05e-06	0.000172	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—TP53—skin cancer	3.04e-06	0.000172	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—TP53—skin cancer	3.02e-06	0.000171	CbGpPWpGaD
Iloperidone—HTR2A—Signaling by GPCR—IL6—skin cancer	3.02e-06	0.00017	CbGpPWpGaD
Iloperidone—HRH1—Signaling by GPCR—IL6—skin cancer	3.01e-06	0.00017	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling by GPCR—IL6—skin cancer	2.96e-06	0.000167	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—KRAS—skin cancer	2.95e-06	0.000166	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—NRAS—skin cancer	2.95e-06	0.000166	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—NRAS—skin cancer	2.93e-06	0.000165	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—HRAS—skin cancer	2.91e-06	0.000164	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—TP53—skin cancer	2.91e-06	0.000164	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—KRAS—skin cancer	2.91e-06	0.000164	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—HRAS—skin cancer	2.91e-06	0.000164	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—HRAS—skin cancer	2.89e-06	0.000163	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling by GPCR—HRAS—skin cancer	2.87e-06	0.000162	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—NRAS—skin cancer	2.85e-06	0.000161	CbGpPWpGaD
Iloperidone—HTR6—Signaling Pathways—IL6—skin cancer	2.79e-06	0.000157	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—HRAS—skin cancer	2.79e-06	0.000157	CbGpPWpGaD
Iloperidone—HTR7—Signaling Pathways—IL6—skin cancer	2.79e-06	0.000157	CbGpPWpGaD
Iloperidone—HTR1D—Signaling Pathways—IL6—skin cancer	2.77e-06	0.000156	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling by GPCR—IL6—skin cancer	2.75e-06	0.000155	CbGpPWpGaD
Iloperidone—DRD4—Signaling Pathways—IL6—skin cancer	2.67e-06	0.00015	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—TP53—skin cancer	2.62e-06	0.000148	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—NRAS—skin cancer	2.59e-06	0.000146	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—TP53—skin cancer	2.59e-06	0.000146	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—NRAS—skin cancer	2.55e-06	0.000144	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—NRAS—skin cancer	2.54e-06	0.000143	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—KRAS—skin cancer	2.54e-06	0.000143	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—ERCC2—skin cancer	2.53e-06	0.000143	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—KRAS—skin cancer	2.53e-06	0.000142	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—HRAS—skin cancer	2.51e-06	0.000142	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—NRAS—skin cancer	2.49e-06	0.000141	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—HRAS—skin cancer	2.48e-06	0.00014	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—KRAS—skin cancer	2.46e-06	0.000139	CbGpPWpGaD
Iloperidone—DRD1—Signaling Pathways—IL6—skin cancer	2.4e-06	0.000135	CbGpPWpGaD
Iloperidone—DRD3—Signaling Pathways—IL6—skin cancer	2.37e-06	0.000134	CbGpPWpGaD
Iloperidone—CYP2D6—Metabolism—PTGS2—skin cancer	2.32e-06	0.000131	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—NRAS—skin cancer	2.32e-06	0.000131	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—TP53—skin cancer	2.26e-06	0.000127	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—TP53—skin cancer	2.24e-06	0.000127	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—KRAS—skin cancer	2.23e-06	0.000126	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—KRAS—skin cancer	2.19e-06	0.000124	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—KRAS—skin cancer	2.19e-06	0.000123	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—TP53—skin cancer	2.18e-06	0.000123	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—HRAS—skin cancer	2.16e-06	0.000122	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—KRAS—skin cancer	2.15e-06	0.000121	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—HRAS—skin cancer	2.15e-06	0.000121	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—HRAS—skin cancer	2.09e-06	0.000118	CbGpPWpGaD
Iloperidone—HTR1A—Signaling Pathways—IL6—skin cancer	2.06e-06	0.000116	CbGpPWpGaD
Iloperidone—HTR2C—Signaling Pathways—IL6—skin cancer	2.05e-06	0.000116	CbGpPWpGaD
Iloperidone—ADRA2C—Signaling Pathways—IL6—skin cancer	2e-06	0.000113	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—KRAS—skin cancer	1.99e-06	0.000113	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—TP53—skin cancer	1.98e-06	0.000112	CbGpPWpGaD
Iloperidone—CYP1A2—Metabolism—PTGS2—skin cancer	1.97e-06	0.000111	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—TP53—skin cancer	1.95e-06	0.00011	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—TP53—skin cancer	1.94e-06	0.00011	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—TP53—skin cancer	1.91e-06	0.000108	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—HRAS—skin cancer	1.89e-06	0.000107	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—HRAS—skin cancer	1.86e-06	0.000105	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—HRAS—skin cancer	1.86e-06	0.000105	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—HRAS—skin cancer	1.82e-06	0.000103	CbGpPWpGaD
Iloperidone—DRD2—Signaling Pathways—IL6—skin cancer	1.81e-06	0.000102	CbGpPWpGaD
Iloperidone—HTR2A—Signaling Pathways—IL6—skin cancer	1.78e-06	0.000101	CbGpPWpGaD
Iloperidone—HRH1—Signaling Pathways—IL6—skin cancer	1.78e-06	0.0001	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—TP53—skin cancer	1.77e-06	0.0001	CbGpPWpGaD
Iloperidone—ADRA1A—Signaling Pathways—IL6—skin cancer	1.75e-06	9.85e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—HRAS—skin cancer	1.7e-06	9.56e-05	CbGpPWpGaD
Iloperidone—ADRA2A—Signaling Pathways—IL6—skin cancer	1.62e-06	9.15e-05	CbGpPWpGaD
Iloperidone—CYP3A4—Metabolism—PTGS2—skin cancer	1.52e-06	8.56e-05	CbGpPWpGaD
